AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03289403
Drug: Immunomodulatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D before ICSI cycle.~Moreover, patients will receive a treatment course of immunomodulatory drugs for 3 -6 months before ICSI cycle:~1. Prednisnlone 40mg for 2 weeks to be lowered gradually till become 5mg after 6 weeks and to be continued~2. Hydroxychloroquine according to body weight, patients who develop hypersensitivity will be shifted to Azathioprin.~3. Immunoglobulins will be used in cases not responding to treatment.
Trial: NCT03781128
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo in an identical-looking vial as LSD, per os, 3 times within 3 weeks
Trial: NCT02925416
Drug: Placebo (D5W)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT03084380
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered at dose of 40mg/kg for 1 day and then fludarabine will be given for the next 5 days and then the T cells will be administered
Trial: NCT02825797
Drug: 3BNC117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 3BNC117
Trial: NCT02825797
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of placebo (sterile saline)
Trial: NCT02872506
Drug: Anti TNF
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are admitted to day hospital with blood test less than 7 days. In the absence of contraindications, hydrocortisone infusion 200 mg will be conducted for 15 minutes followed by anti-TNF treatment infusion over 2 hours for the first three sessions. The following infusions of anti-TNF therapy will be on the same terms without hydrocortisone, every 4 to 8 weeks, in doses of 5-10mg/kg. Adverse effect most frequently reported was URTI. The most serious adverse reactions, were a reactivation of hepatitis B, congestive heart failure, serious infection, serum hypersensitivity reactions, blood diseases, systemic lupus erythematosus / lupus-like syndrome, demyelinating disorders, hepatobiliary metabolism disorders. The QOL will be assessed by IBDQ score at the inclusion visit before the first infusion and at 6 months.
Trial: NCT02074891
Drug: coformulated TDF/FTC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral dose of coformulated TDF/FTC
Trial: NCT02727699
Drug: Xanamem™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xanamem™ is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343
Trial: NCT02727699
Drug: Placebo (for Xanamem™)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Excipient blend capsules manufactured to mimic Xanamem™ capsules
Trial: NCT01975129
Drug: Vagitocin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04082533
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will be receiving 100 mg intravenous hydrocortisone every 8 hours, starting in the holding area roughly 2 hours prior to first incision.
Trial: NCT00943826
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously q2w in the Concurrent and Maintenance Phases and q3w in the Monotherapy Phase.
Trial: NCT04189666
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: compare the ability of the drug in preventing postoperative delirium
Trial: NCT04090775
Drug: Opdivo Injectable Product
RxNorm normalized name: Opdivo Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opdivo (nivolumab): PD-1 inhibitor antibody~Injectable 10mg/mL, only 1 mL injected.
Trial: NCT04090775
Drug: Yervoy Injectable Product
RxNorm normalized name: Yervoy Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yervoy (ipilimumab): Anti-CTLA-4 antibody~Injectable 5mg/mL, only 1 mL injected.
Trial: NCT00848666
Drug: Topical therapy
RxNorm normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One time immersion of the feet in a liquid containing water, alcohol, vinegar, benzoic acid and salicylic acid for a total of 30 minutes.
Trial: NCT04034524
Drug: GLP-1 receptor agonist
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: any GLP-1 receptor agonist (other than Saxenda or liraglutide 3.0mg)
Trial: NCT00517868
Drug: URG101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bladder instillation of URG101 or Placebo in random order on treatment 1 and treatment 2 followed by an open-label URG101 on treatment 3 within the same week.
Trial: NCT00517868
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid formulation without active URG101 drug components
Trial: NCT01470352
Drug: Doluxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/d
Trial: NCT01470352
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suger pill 30mg/d
Trial: NCT02705664
Drug: Loceryl Nail Lacquer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical over entire toenail plates of affected toenails once weekly in the evening (at bed time) after having filled down affected toenails to gently remove as much as affected nails and having cleaned toenails surfaces with the provided cleansing swab
Trial: NCT02705664
Drug: Urea Ointment
RxNorm normalized name: Urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical over the infected part of the toenails only once daily under occlusion in the evening (at bed time) after having soaked toenails in warm water and having removed the soften infected toenail plates and dried the toenails
Trial: NCT00907179
Drug: LBH 589
RxNorm normalized name: CATHETER,EXTERNAL MEDIUM LBH #451-7658
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LBH589 three-times-a-week (doses will be at least 2 days apart, e.g. Monday, Wednesday, Friday), until disease progression or intolerable toxicities LBH589 will start the week prior to the first pemetrexed cycle and PD studies will be performed (week -1).~Dose level: 1 LBH589: 10 mg Pemetrexed: 500 mg/m2~Dose level: 2 LBH589: 15 mg Pemetrexed: 500 mg/m2~Dose level: 3 LBH589: 20 mg Pemetrexed: 500 mg/m2~Dose level: 4 LBH589: 30 mg Pemetrexed: 500 mg/m2
Trial: NCT00472004
Drug: 17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined, 1 Daily, 1 year duration
Trial: NCT00576849
Drug: Balanced HES 130/0.42
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume is administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) was \<60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is \<10 mmHg
Trial: NCT00576849
Drug: Balanced HES 130/0.42
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume will be administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) is \<60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is \<10 mmHg
Trial: NCT02480946
Drug: MBS2320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As described in the arm descriptions
Trial: NCT02480946
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As described in the arm descriptions
Trial: NCT02480946
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Background therapy as described in the arm descriptions
Trial: NCT00830895
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAD001 10mg/day
Trial: NCT01721941
Drug: Phase I Dose level -1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
Trial: NCT01721941
Drug: Phase I dose level 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
Trial: NCT01721941
Drug: Phase I Dose level 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
Trial: NCT04648033
Drug: Standard of care chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atovaquone, cisplatin and vinorelbine are all considered Investigational Medicinal Products (IMPs) in this trial due to the investigation of these drugs in a novel combination. Patients will receive two 21-day cycles of cisplatin and vinorelbine chemotherapy, comprising 80 mg/m2 cisplatin on days 1 \& 22 of their CRT treatment and 15 mg/m2 vinorelbine on days 1, 8, 22 \& 29.
Trial: NCT00000549
Drug: progestins
RxNorm normalized name: PROGESTINS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00433511
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00433511
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02495038
Drug: 10% reduction of combination of Esmeron® and Nimbex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were randomly assigned to each group by opening of sealed allocation envelope. After collection of data, allocation number was matched with each group. The participants matched at Group S were administered with NMBAs reduced 10% of each ED95. Before patients arrived in the operating room, rocuronium and cisatracurium were prepared by a nurse who was not involved in this study. Each drug dosage was determined by allocation number. The syringe containing each study drug was conveyed to the performer of this study as the status of shielding the scale. The syringes of rocuronium and cisatracurium used each other syringe.
Trial: NCT02495038
Drug: 20% reduction of combination of Esmeron® and Nimbex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants matched at Group L were administered with NMBAs reduced 20% of each ED95.
Trial: NCT01600625
Drug: oral minocycline hydrochloride treatment
RxNorm normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally received 50 mg minocycline (Minocin, SK chemical, Seoul, Korea) twice a day for 2 months treatment
Trial: NCT03759301
Drug: Growth Hormones Somatropin Recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormones Somatropin Recombinant 4 IU/day subcutaneous from the 2nd day of the cycle and stopped 1 day before ovum pickup
Trial: NCT03759301
Drug: Placebo saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: same volume as growth hormone ampule used
Trial: NCT00496600
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAD001 will be taken orally starting at a dose of 30 mg every week for the first cohort of patients, one hour prior to administration of patupilone. Patupilone will then be administered as an infusion, starting at 5 mg/m2 for the first cohort of patients. The dosage and scheduling of RAD001 and patupilone during each 21-day cycle will vary according to cohort assignment
Trial: NCT01675089
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The treatment group will receive 15-minute intravenous administration of zoledronic acid (5 mg) in a single dose at the time of kidney transplantation and vitamin D replacement. The aim of vitamin D replacement will be serum levels of 25 (OH) vitamin D above 30 ng/ml.
Trial: NCT00973011
Drug: FCFD4514S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal escalating dose
Trial: NCT00327080
Drug: Acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01550653
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02086513
Drug: LDE225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with LDE225
Trial: NCT00512057
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01300013
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 48-hour infusion of placebo
Trial: NCT04635800
Drug: MHU650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MHU650 powder for solution for injection
Trial: NCT02587117
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each capsule contain 20 mg prednisolone. Each patient was received two capsules of prednisolone (total dose was 40 mg) single dose in morning for 2 months. Follow-up was done at base line, 2nd, 4th, 6th and 8th weeks of the therapy.
Trial: NCT03329014
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control arm
Trial: NCT01685398
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03387111
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Trial: NCT03387111
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Trial: NCT03387111
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Trial: NCT03387111
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
Trial: NCT05279391
Drug: Low molecular weight heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic doses of LMWH (e.g. Tinzaparin 175IU/kg)
Trial: NCT01601600
Drug: BYM338
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BYM338
Trial: NCT01601600
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BYM338 Placebo
Trial: NCT03140358
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00855270
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV saline will be used as placebo for control
Trial: NCT00855270
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single dose 90-150mg of Intra Venous Hydrocortisone. 90mg will be administrated to participants weighing 45-59kg. 100mg will be administrated to participants weighing 60-69kg. 120mg will be administrated to participants weighing 70-89kg. 140mg will be administrated to participants weighing 90-99kg. 150mg will be administrated to participants weighing 100-120kg.
Trial: NCT03846739
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo nasal sprays contain identical ingredients except for the peptide itself.
Trial: NCT00093444
Drug: lyso-thermosensitive liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00029159
Drug: androgen
RxNorm normalized name: Androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone or placebo capsule, .06mg/kg/day, orally, for 2 years
Trial: NCT04518995
Drug: CTP-543 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as tablets.
Trial: NCT02732275
Drug: DS-3201b
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-3201 to be administered orally once daily in each 28-day cycle.
Trial: NCT01282970
Drug: Placebo to BI 135585
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral doses given to approximately 5-6 parallel groups of 12 subjects (9 on active and 3 on placebo) over 14 days
Trial: NCT00639743
Drug: placebo ( group B)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo ( group B)
Trial: NCT02732275
Drug: DS-3201b
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-3201 to be administered orally once daily in each 28-day cycle at the recommended dose for expansion.
Trial: NCT00281658
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel Matching Placebo
Trial: NCT02607553
Drug: G-202
RxNorm normalized name: krill/om-3/dha/epa/phospho/ast 500 mg-86 mg-25 mg-40 mg-202 mg-101 mcg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle until disease progression
Trial: NCT01916863
Drug: LX4211 400 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01916863
Drug: LX4211 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02551991
Drug: nal-IRI
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02551991
Drug: 5 fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02551991
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03467100
Drug: XEN901
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule filled with XEN901
Trial: NCT03467100
Drug: Inert Ingredients Oral Product
RxNorm normalized name: inert ingredients Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule
Trial: NCT00043329
Drug: Actimmune Registry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as administered by physician
Trial: NCT03576794
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in both groups will receive prednisolone 15 mg once daily and will be randomized within 4 weeks of the start of glucocorticoid therapy (prednisolone). Prednisolon will be tapered according to a short fixed protocol with a slow gradual taper till 0 in week 27.
Trial: NCT01884909
Drug: 'TOPROL-XL®' ER Tablets 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 \* 200 mg tablet per day
Trial: NCT00120380
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00659347
Drug: DOV 21, 947
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, 25 mg, 2 capsules (1 Active/1 Placebo) BID, 2 weeks Capsules, 25 mg, 2 capsules (2 Active) BID, 2 weeks
Trial: NCT00659347
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules,25 mg,BID,6weeks
Trial: NCT02236182
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04278404
Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The prescribing of drugs to children is not part of this protocol. Participants will receive DOIs as prescribed by their treating provider.
Trial: NCT00170898
Drug: Lumiracoxib
RxNorm normalized name: Lumiracoxib
DrugBank: Lumiracoxib (DB01283)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01448213
Drug: Prednisolone acetate
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects assigned to Treatment Regimen A will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for 3 months, then 3 times a day for one month, then twice a day for one month, then once a day until the subject exits the study.
Trial: NCT03351205
Drug: estradiol valerate tablets+dydrogesterone tablets
RxNorm normalized name: dydrogesterone / estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral estradiol valerate tablets+dydrogesterone tablets
Trial: NCT01267968
Drug: GSK2251052
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg (dosing detailed in Arm description)
Trial: NCT00680238
Drug: Human derived FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Customized for each patient
Trial: NCT00419718
Drug: inhaled human insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00791973
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 puffs in each nostril once daily for 1 week
Trial: NCT01408836
Drug: Intravenous methyl prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methyl prednisolone
Trial: NCT01275170
Drug: MK-7655
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg intravenous (IV) over 30 minutes as a single dose
Trial: NCT01275170
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine caplet, single 200 mg dose, orally
Trial: NCT03372772
Drug: Levocarnitine
RxNorm normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levocarnitine syrup- Oral supplementation about 2000mg/ day for 8 weeks
Trial: NCT00301925
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00301925
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes